1st Quarter - Termination

SALT POINT STRATEGIES for VERTEX PHARMACEUTICALS

Firm
Client
Income
$10,000
Expenses
—
Terminated
Jan 31, 2026

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Non-opioid pain relief and drug pipeline issues.

LobbyistCovered position, as disclosed
ADAM BUCKALEW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.